dengu
viru
denv
transmit
bite
mosquito
aed
genu
caus
approxim
million
infect
annual
denv
belong
genu
flaviviru
famili
flavivirida
singlestrand
posit
sens
rna
genom
approxim
kb
length
genom
denv
contain
singl
open
read
frame
encod
polyprotein
precursor
cleav
three
structur
protein
capsid
c
premembran
prm
envelop
e
protein
seven
nonstructur
protein
role
pathogenhost
interact
pathogenesi
patient
denv
infect
usual
asymptomat
howev
day
infect
mosquito
bite
patient
exhibit
extrem
symptom
includ
headach
vomit
fever
rash
myalgia
retroorbit
pain
moreov
patient
progress
lifethreaten
sever
denv
infect
character
cn
impair
multipl
organ
failur
plasma
leakag
sever
bleed
dengu
hemorrhag
fever
dengu
shock
syndrom
date
effect
antivir
drug
avail
block
denv
infect
addit
function
anthelmint
drug
niclosamid
wide
report
confer
broad
antivir
activ
zika
viru
member
flaviviru
genu
report
inhibit
niclosamid
treatment
unknown
therapeut
mechan
niclosamid
like
inhibit
zika
denv
infect
undefin
target
flaviviru
proteas
repurpos
applic
niclosamid
antiflaviviru
therapi
propos
strategi
howev
niclosamid
also
confer
multifacet
block
effect
differ
viru
infect
well
tumorigenesi
epsteinbarr
viru
infect
niclosamid
suppress
viral
lytic
replic
inhibit
mtor
mammalian
target
rapamycin
activ
addit
niclosamid
exhibit
anticanc
activ
block
mtor
transduc
activ
transcript
nuclear
factor
kappalightchainenhanc
activ
b
cell
signal
pathway
although
molecul
report
involv
viral
infect
target
mtor
may
facilit
denv
replic
autophagi
induct
potent
antivir
effect
niclosamid
denv
infect
warrant
investig
infecti
process
denv
includ
viral
adher
receptormedi
entri
endocytosismedi
fusion
uncoat
endosom
follow
endosom
acidif
rna
releas
replic
protein
translat
virion
assembl
releas
target
process
propos
antivir
strategi
follow
endocytosi
endosom
acidif
lead
fusion
viral
envelop
protein
host
membran
facilit
releas
viral
genom
vacuolartyp
hatpas
vatpas
protonpump
enzym
gener
low
intravacuolar
ph
requir
denv
endocytosi
infect
vitro
genet
pharmacolog
target
vatpas
effect
retard
denv
infect
vivo
jurgeit
et
al
demonstr
niclosamid
act
proton
carrier
block
endosom
acidif
inhibit
human
rhinoviru
influenza
viru
infect
use
previou
vitro
vivo
model
denv
infect
investig
possibl
antivir
effect
molecular
action
niclosamid
block
denv
infect
murin
cell
atcc
human
atcc
babi
hamster
kidney
bhk
cell
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
life
technolog
rockvil
md
aed
albopictu
cell
atcc
grown
plastic
rpmi
medium
rpmi
invitrogen
life
technolog
cultur
media
supplement
heatinactiv
fetal
bovin
serum
fb
invitrogen
life
technolog
uml
penicillin
streptomycin
taiwanes
human
isol
obtain
center
diseas
control
taiwan
propag
cell
viral
titer
quantifi
plaqu
assay
use
cell
accordingli
follow
reagent
antibodi
use
studi
niclosamid
mtor
inhibitor
rapamycin
inhibitor
cucurbitacin
inhibitor
bay
vatpas
inhibitor
bafilomycin
protonophor
carbonyl
cyanid
mchlorophenyl
hydrazon
cccp
carbonyl
cyanideptrifluoromethoxyphenylhydrazon
fccp
hoechst
dimethyl
sulfoxid
dmso
acridin
orang
mous
mab
specif
sigmaaldrich
st
loui
mo
antibodi
akt
akt
cell
signal
technolog
beverli
antibodi
dsrna
denv
capsid
e
genetex
san
antonio
tx
polyclon
antirabbit
iii
mbl
intern
nagoya
japan
goat
antirabbit
igg
conjug
hrp
chemicon
intern
temecula
ca
rabbit
antimous
igg
conjug
hrp
abcam
cambridg
alexa
fluor
goat
antimous
invitrogen
carlsbad
ca
anim
experi
perform
accord
guidelin
anim
protect
act
taiwan
protocol
accord
guidelin
establish
ministri
scienc
technolog
taiwan
approv
laboratori
anim
care
use
committe
nation
cheng
kung
univers
approv
number
iacuc
sevendayold
icr
suckl
mice
inocul
intracerebr
plaqueform
unit
pfu
intraperiton
pfu
combin
without
niclosamid
mgkg
treatment
day
postinfect
brain
tissu
harvest
protein
assay
bodi
weight
diseas
score
carri
accord
previou
studi
cell
resuspend
concentr
cellsml
appropri
medium
denv
moi
incub
h
cell
wash
cultur
medium
incub
indic
time
presenc
viral
supernat
evalu
use
plaqu
assay
cell
plate
onto
plate
cellswel
adsorpt
serial
dilut
viru
solut
h
solut
replac
fresh
dmem
contain
fb
methyl
cellulos
sigmaaldrich
five
day
postinfect
medium
remov
cell
fix
stain
crystal
violet
solut
contain
crystal
violet
nacl
formalin
cell
cytotox
assess
use
cytotox
detect
kit
assay
roch
diagnost
lew
uk
accord
manufactur
instruct
total
cell
lysat
extract
buffer
contain
triton
mm
tri
ph
mm
edta
proteas
inhibitor
mixtur
roch
appli
scienc
indianapoli
protein
separ
use
sd
polyacrylamid
gel
electrophoresi
transfer
polyvinyliden
difluorid
membran
millipor
corpor
billerica
block
blot
probe
indic
antibodi
develop
use
enhanc
chemiluminesc
pierc
rockford
il
follow
densitometrybas
quantif
analysi
use
imagej
softwar
http
rsbwebnihgovij
rel
densiti
identifi
protein
calcul
cell
harbor
luciferaseexpress
denv
replicon
gener
maintain
accord
previou
studi
fluoresc
denv
prepar
label
alexa
fluor
succinimidyl
ester
molecular
probe
invitrogen
refer
previou
studi
label
virus
purifi
use
amicon
pltk
ultracelpl
membran
kda
centrifug
filter
unit
millipor
remov
excess
dye
cell
wash
twice
inocul
moi
cell
h
cell
visual
laserscan
confoc
microscop
leica
tc
confoc
microscop
leica
microsystem
mannheim
germani
analyz
use
facscanto
ii
flow
cytomet
bd
bioscienc
franklin
lake
nj
threedimension
imag
reconstruct
seri
confoc
imag
along
zaxi
cell
analysi
zstack
reconstruct
use
leica
confoc
softwar
cell
fix
paraformaldehyd
permeabil
triton
wash
twice
icecold
phosphatebuff
salin
cell
first
probe
antidsrna
antibodi
probe
alexa
goat
antimous
igg
dapi
use
nuclear
stain
cell
visual
fluoresc
microscop
evo
fl
cell
imag
system
thermo
fisher
scientif
waltham
analyz
use
flow
cytometri
attun
nxt
mean
fluoresc
intens
mfi
dsrna
analyz
imagej
softwar
concentr
cellcondit
cultur
medium
determin
use
elisa
kit
pbl
assay
scienc
piscataway
nj
accord
manufactur
instruct
cell
treat
ngml
acridin
orang
ao
sigmaaldrich
serumfre
cultur
medium
min
wash
hank
balanc
salt
solut
twice
cell
visual
fluoresc
microscop
evo
data
obtain
three
independ
experi
present
mean
standard
deviat
sd
two
set
data
analyz
unpair
student
test
three
set
data
analyz
oneway
anova
tukey
multiplecomparison
test
statist
signific
set
p
niclosamid
confer
potenti
antiflaviviru
activ
zika
viru
infect
target
unknown
factor
hypothes
treatment
niclosamid
inhibit
zika
viru
also
flaviviru
denv
verifi
antivir
effect
niclosamid
denv
infect
vitro
cell
model
denv
infect
examin
viral
protein
express
viral
releas
releas
ldh
measur
monitor
cytotox
cell
found
treatment
niclosamid
subleth
dose
caus
minor
cytotox
effect
cell
fig
evalu
cytotox
concentr
niclosamidetr
cell
use
ldh
assay
show
valu
less
fig
cytotox
respons
assess
rhodamin
stain
monitor
mitochondri
membran
potenti
loss
carri
exclud
lethal
dose
niclosamid
use
studi
fig
niclosamid
effect
block
viral
protein
express
fig
significantli
p
retard
viral
releas
fig
addit
niclosamid
show
valu
half
maxim
effect
concentr
near
fig
usag
niclosamid
pre
coadministr
posttreat
significantli
p
inhibit
denv
replic
fig
result
confirm
antivir
effect
niclosamid
treatment
denv
infect
vitro
next
investig
possibl
antivir
action
niclosamid
cellular
respons
infecti
process
denv
infect
explor
previous
demonstr
infect
denv
cell
cytotox
effect
niclosamid
subleth
dose
monitor
fig
western
blot
result
show
inhibit
denv
protein
express
presenc
niclosamid
treatment
confirm
antivir
effect
niclosamid
denvinfect
cell
fig
demonstr
infect
efficaci
cell
perform
fluoresc
denv
stain
follow
confoc
microscop
observ
fig
well
flow
cytometr
analysi
fig
result
show
viral
endocytosi
h
postinocul
retard
niclosamid
treatment
find
exclud
possibl
niclosamid
block
viral
endocytosi
earli
stage
denv
infect
identifi
target
niclosamid
underli
antivir
capac
type
ifn
respons
monitor
regard
potent
antivir
effect
respons
denv
infect
denvinfect
cell
quantifi
elisa
product
significantli
p
increas
fig
next
examin
whether
niclosamid
treatment
enhanc
product
reduc
denv
infect
howev
result
reveal
niclosamid
significantli
p
decreas
product
fig
probabl
follow
earli
blockad
viral
infect
data
impli
role
niclosamid
independ
facilit
antivir
type
ifn
respons
next
examin
step
viral
cell
cycl
assess
firefli
luciferas
activ
cell
found
treatment
niclosamid
caus
neither
direct
inhibitori
effect
repliconbas
assay
viral
genom
translat
replic
fig
cytotox
cell
fig
result
indic
block
denv
infect
niclosamid
direct
inhibitori
effect
fluc
activ
cell
niclosamid
confer
multipl
therapeut
effect
treatment
cancer
infect
metabol
diseas
interf
activ
mtor
signal
pathway
next
examin
effect
niclosamid
mtor
activ
timekinet
assay
reveal
decreas
phosphoryl
akt
niclosamidetr
cell
fig
data
indic
treatment
niclosamid
caus
mtor
inhibit
due
action
abolish
associ
raptor
regulatori
associ
protein
mtor
mtor
rapamycin
use
classic
inhibitor
treatment
rapamycin
effect
deactiv
erk
akt
fig
next
evalu
effect
mtor
inhibit
denv
infect
studi
consist
previou
studi
rapamycin
report
promot
denv
infect
autophagi
rapamycin
treatment
enhanc
express
viral
protein
induc
autophagi
convers
fig
significantli
p
facilit
viral
releas
fig
furthermor
treatment
inhibitor
block
neither
viral
protein
express
fig
viral
releas
fig
suggest
independ
role
possibl
target
pathway
taken
togeth
result
indic
niclosamid
confer
antimtor
activ
antidengu
activ
niclosamid
mediat
mtorindepend
pathway
structureact
assay
design
niclosamid
protonophor
lower
cytoplasm
ph
caus
mtor
inactiv
endosom
denv
requir
lowphdepend
fusion
infecti
genom
entri
cytoplasm
phsensit
dye
ao
use
examin
whether
select
drug
neutral
low
ph
endosom
denv
infect
result
reveal
low
ph
endosom
red
denvinfect
cell
attenu
treatment
niclosamid
protonophor
cccp
fccp
vatpas
inhibitor
bafilomycin
fig
cell
niclosamid
treatment
shown
green
suggest
ph
neutral
endosom
acidif
block
assess
viral
uncoat
process
timekinet
express
denv
e
protein
reveal
niclosamid
interrupt
e
protein
degrad
earli
fusion
stage
denv
infect
fig
furthermor
denv
dsrna
replic
detect
immunostain
fig
viral
releas
determin
plaqu
assay
fig
significantli
p
decreas
niclosamid
cccp
fccp
result
reveal
niclosamid
caus
endosom
deacidif
inhibit
dsrna
replic
viral
releas
denv
infect
verifi
antivir
effect
niclosamid
denv
infect
vivo
viral
replic
viral
enceph
mortal
denvinfect
icr
suckl
mice
monitor
accordingli
anim
studi
sevendayold
icr
suckl
mice
inocul
concurr
intracrani
intraperiton
inject
without
niclosamid
mgkg
cotreat
fig
accord
western
blot
analysi
viral
protein
fig
plaqu
assay
detect
product
infecti
particl
fig
denv
caus
signific
infect
replic
mous
brain
day
postinfect
niclosamid
inhibit
viral
protein
express
replic
next
monitor
timekinet
chang
clinic
score
grade
accord
sever
ill
follow
healthi
minor
ill
includ
weight
loss
reduc
mobil
hunchback
bodi
orient
limbic
seizur
move
difficulti
anterior
limb
posterior
limb
weak
paralysi
death
previous
describ
first
denv
infect
caus
dramat
loss
bodi
weight
timedepend
manner
howev
niclosamid
revers
effect
fig
signific
increas
clinic
score
fig
occur
denvinfect
mice
compar
mockinfect
mice
day
postinfect
surviv
rate
denvinfect
mice
decreas
day
postinfect
mice
die
day
postinfect
fig
cotreat
niclosamid
slightli
reduc
denvinduc
diseas
progress
mortal
data
indic
singledos
treatment
niclosamid
partli
abolish
encephalit
denv
infect
model
lead
neural
impair
follow
viral
replic
accord
find
treatment
antiparasit
agent
niclosamid
confer
antivir
activ
includ
effect
viral
genom
releas
viral
protein
express
dsrna
replic
viral
releas
vitro
sever
denvinfect
cell
line
also
demonstr
singledos
administr
niclosamid
partli
reduc
denv
replic
vivo
well
denvinduc
acut
viral
encephalitislik
symptom
includ
progress
hunchback
postur
limbic
seizur
limbic
weak
paralysi
lethal
find
along
current
studi
show
niclosamid
confer
antivir
activ
replic
flavivirus
zika
denv
other
demonstr
potenti
applic
niclosamid
treatment
inhibit
denv
infect
vitro
vivo
addit
action
denv
niclosamid
demonstr
antivir
agent
sever
acut
respiratori
syndrom
coronaviru
human
rhinovirus
influenza
viru
chikungunya
viru
ebv
zika
repurpos
niclosamid
antivir
agent
therefor
propos
examin
antivir
action
niclosamid
inconsist
previou
studi
show
niclosamid
inhibit
entri
chikungunya
viru
cell
result
show
minor
effect
endocytosi
denv
niclosamidetr
cell
target
niclosamid
block
viral
entrybind
address
furthermor
monitor
antivir
respons
denvinfect
cell
reveal
immun
enhanc
niclosamid
stimul
contrast
niclosamid
reduc
product
like
suppress
denv
infect
prior
antivir
immun
activ
gener
niclosamid
shown
block
glucos
uptak
oxid
phosphoryl
anaerob
metabol
kill
tapeworm
addit
niclosamid
inhibit
notch
signal
pathway
investig
niclosamideinduc
antivir
action
valid
need
denv
replicon
cell
gener
assess
replic
denv
genom
howev
niclosamid
alter
viral
translat
denv
replicon
cell
studi
although
replicon
cell
contain
host
viral
factor
need
viral
genom
replic
find
reveal
antidenv
activ
niclosamid
independ
factor
current
screen
approv
investig
drug
niclosamid
identifi
potenti
viral
inhibitor
target
format
proteas
flavivirus
zika
denv
consid
matur
denv
particl
requir
cleavag
viral
precursor
polyprotein
directact
antivir
agent
smallmolecul
diaryl
thio
ether
cyclic
peptid
target
proteas
promis
antivir
candid
shown
li
et
al
three
potent
inhibitor
proteas
includ
niclosamid
temoporfin
nitazoxanid
confirm
inhibit
complex
format
denv
moreov
compound
shown
reduc
viral
replic
denv
vitro
human
cell
given
niclosamidebas
antivir
properti
target
denv
least
part
could
implement
reduc
viral
replic
niclosamid
also
exhibit
multipletarget
effect
cellular
signal
pathway
mtor
inconsist
niclosamid
inhibitor
reduc
denv
infect
mtor
inhibitor
enhanc
denv
replic
recent
studi
show
niclosamid
inhibit
sodium
butyrateinduc
mtor
activ
ebv
lytic
replic
mechanist
studi
indic
niclosamid
possess
protonophor
activ
dissip
proton
endosomeslysosom
cytosol
result
increas
proton
effect
lower
cytoplasm
ph
caus
mtor
inactiv
howev
inhibit
mtor
follow
autophag
induct
facilit
denv
replic
like
modul
lipid
metabol
promot
cell
surviv
studi
comparison
directact
mtor
inhibitor
rapamycin
niclosamid
also
inhibit
phosphoryl
akt
induc
convers
autophagi
contrast
rapamycin
effect
enhanc
denv
replic
indic
enhanc
role
autophagi
denv
infect
although
denv
promot
increas
autophagi
niclosamid
treatment
inhibit
infecti
process
denv
prior
induct
autophagyfacilit
denv
replic
endosom
acidif
follow
viral
rna
releas
requir
denv
replic
target
vatpas
protonpump
enzym
inhibit
viral
releas
endosom
vitro
decreas
denv
infect
neurotox
vivo
report
jurgeit
et
al
niclosamid
act
proton
carrier
block
endosom
acidif
also
provid
evid
confirm
inhibit
denvinduc
endosom
acidif
viral
e
protein
degrad
dsrna
replic
viral
releas
treatment
protonophor
niclosamid
cccp
fccp
retard
denv
viral
genom
releas
interf
endosom
acidif
could
anoth
strategi
util
antivir
capabl
niclosamid
although
li
et
al
show
niclosamid
treatment
block
complex
format
vitro
specul
niclosamideinduc
endosom
deacidif
retard
earli
process
denv
infect
rather
block
use
previou
vivo
model
denv
infect
show
denv
caus
replic
brain
follow
acut
viral
encephalitislik
symptom
mice
show
niclosamid
reduc
viral
replic
also
partli
retard
lethal
deninfect
mice
studi
verifi
antivir
activ
niclosamid
sever
denvinfect
cell
line
vitro
mous
model
denv
infect
vivo
use
possibl
effect
niclosamid
infecti
process
verifi
use
appropri
test
system
found
niclosamid
similar
protonophor
cccp
fccp
inhibit
endosom
acidif
reduc
viral
genom
releas
independ
inhibit
mtor
signal
pathway
without
effect
denv
endocytosi
antivir
ifn
respons
viral
translat
coadministr
singl
dose
niclosamid
partli
decreas
denvinduc
acut
viral
encephalitislik
symptom
mortal
modifi
treatment
multipl
dose
need
valid
therapeut
efficaci
although
denv
replic
may
block
niclosamid
vitro
vivo
howev
concurr
block
proinflammatori
andor
neurotox
factor
induc
denv
infect
neuroprotect
also
need
therapeut
consider
dengu
enceph
furthermor
blockad
endosom
acidif
niclosamid
examin
hazard
effect
synapt
activ
neuron
cell
although
niclosamid
caus
endosom
deacidif
independ
vatpas
blockad
conclus
togeth
result
recent
studi
find
highlight
repurpos
applic
niclosamid
antivir
drug
develop
denv
infect
